ArticleHealth research policy and systems2021
Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis.
Article in Health research policy and systems, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Optimal insurance coverage and pricing of outpatient drugs in Iran: a cost- and chronicity-based adaptation of the vertical equity model.International journal for equity in health · 2026Article
- Contribution of Medication Expenditures to Catastrophic Health Expenditures in Iran: An Inequality Analysis.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2026Article
- Quality of Service and Cost of Managing an Episode of Major Depressive Disorder: A Cohort Study in Iran.Archives of Iranian medicine · 2026Article
- Actor-network and stakeholder analysis in preventing health goods smuggling in Iran.Globalization and health · 2025Article
- Stakeholder engagement and pharmaceutical pricing regulation: a qualitative inquiry.Journal of pharmaceutical policy and practice · 2025Article
- Evidence-based practice in traditional persian medicine (TPM): a stakeholder and social network analysis.BMC complementary medicine and therapies · 2024Article
- Drivers of vulnerability to medicine smuggling and combat strategies: a qualitative study based on online news media analysis in Iran.BMC health services research · 2024Article
- Pharmaco-disparities in heart failure: a survey of the affordability of guideline recommended therapy in 10 countries.ESC heart failure · 2023Article
- Policy analysis of the protection of Iranian households against catastrophic health expenditures: a qualitative analysis.BMC health services research · 2023Article
- Eliciting the public preferences for pharmaceutical subsidy in Iran: a discrete choice experiment study.Journal of pharmaceutical policy and practice · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOver the past three decades, allocation of foreign currency subsidies has been the primary strategy of various administrations in Iran to improve access to medicines. This strategy has resulted in several challenges, including stakeholder conflicts of interest.
objectiveTo identify the power, interest, and role of the stakeholders in allocating foreign currency subsidies to medicines in the Iranian health system.
methodsIn this qualitative study, 39 semi-structured interviews were conducted. Key informants were recruited using a purposive sampling technique. The theoretical framework adopted by Varvasovszky and Brugha was employed. The data were analysed using directed content analysis.
resultsThe foreign currency subsidy for medicines included 21 stakeholders in five main categories: governmental organizations, Iranian Parliament, general population, nongovernmental organizations (NGOs), and the pharmaceutical industry. Stakeholders varied in their level of participation and support in the policy-making process. Among them, the Iranian Government, Planning and Budget Organization, the Ministry of Health and Medical Education (MoHME), and Iran Food and Drug Administration (IFDA) were the most important stakeholders, with highly supportive positions, while domestic drug manufacturers were the strongest opponents of this policy. The Government of Iran is the most powerful institution with regard to the ability to allocate foreign currency subsidies to medicines, followed by the MoHME and the IFDA.
conclusionThis study demonstrated that identifying and analysing the stakeholders involved in allocating foreign currency subsidies to medicines can provide valuable information for policy-makers to enable a more comprehensive understanding and better capacity to determine whether or not to eliminate these subsidies. Moreover, decision-making in this process is a long-term issue that requires consensus among all stakeholders. Because of the political and social consequences of eliminating foreign currency subsidies, the necessary political will is not institutionalized. We recommend a step-by-step approach in eliminating foreign currency subsidies if the requirements are met (i.e., those related to the consequences of such interventions). Therefore, revision of the current policy along with these requirements, in addition to financial transparency and enhanced efficiency, will facilitate progress towards achieving the Sustainable Development Goals by improving access to medicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.